Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

mtm grabs another E10m for series C:

This article was originally published in Clinica

Executive Summary

German IVD company mtm laboratories has raised an additional E9.6m ($15.3m) in the third tranche of a series C financing, bringing the total for the round to E31.6m. The fundraising was led by HBM BioVentures and HBM BioCapital, and included the participation of existing shareholders and one new investor, NTEC (National Technology Enterprises Company of Kuwait). Heidelberg-based mtm, which specialises in cervical cancer tests based on its proprietary p16INK4a biomarker, will use the proceeds from third tranche to expand commercialisation of the Cervatec assay, the company's third and latest product launched on the market, and to continue development of other product lines.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel